WHAT IS DNDi DOING TO ADDRESS UNMET TREATMENT NEEDS?

Recognizing an opportunity to test the effectiveness of fosravuconazole in treating mycetoma after experience with this drug as a Chagas agent, DNDi included its clinical testing for the disease in its Business Plan 2015-2023 as a short-term, pragmatic, miniportfolio approach, and in 2016 will begin a clinical study in partnership with the Mycetoma Research Centre in Sudan.

 

DNDi aims to deliver:

  • A new safe, effective and affordable treatment for patients with eumycetoma.